--- title: "Tyra Biosciences (NASDAQ:TYRA) Trading Down 6.7% on Analyst Downgrade" type: "News" locale: "en" url: "https://longbridge.com/en/news/299913699.md" description: "Tyra Biosciences (NASDAQ:TYRA) shares fell 6.7% after HC Wainwright lowered its price target from $30 to $29, despite maintaining a buy rating. The stock traded as low as $24.20 with reduced volume. Other analysts maintain positive ratings, including JonesTrading ($56 target), Wedbush ($53), and Piper Sandler ($56). Institutional investors like Jupiter Topco LLC and BlackRock Inc. increased holdings in Q2. Tyra reported a quarterly EPS miss of ($0.69) versus estimates." datetime: "2026-09-23T14:40:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/299913699.md) - [en](https://longbridge.com/en/news/299913699.md) - [zh-HK](https://longbridge.com/zh-HK/news/299913699.md) generator: "portal-rs" --- # Tyra Biosciences (NASDAQ:TYRA) Trading Down 6.7% on Analyst Downgrade Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) was down 6.7% during mid-day trading on Wednesday after HC Wainwright lowered their price target on the stock from $30.00 to $29.00. HC Wainwright currently has a buy rating on the stock. Tyra Biosciences traded as low as $24.20 and last traded at $23.8660. 160,969 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 926,430 shares. The stock had previously closed at $25.57. Get **Tyra Biosciences** alerts: Several other equities research analysts have also recently weighed in on the stock. JonesTrading started coverage on shares of Tyra Biosciences in a research note on Wednesday, June 17th. They issued a "buy" rating and a $56.00 target price for the company. Wedbush reaffirmed an "outperform" rating and issued a $53.00 price target on shares of Tyra Biosciences in a report on Thursday, September 10th. Piper Sandler reissued an "overweight" rating and set a $56.00 price objective on shares of Tyra Biosciences in a report on Tuesday, September 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Tyra Biosciences in a research report on Friday, July 17th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Tyra Biosciences in a research note on Thursday, September 10th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $46.89. **Get Our Latest Stock Analysis on Tyra Biosciences** ## Institutional Investors Weigh In On Tyra Biosciences Large investors have recently modified their holdings of the stock. Jupiter Topco LLC bought a new stake in Tyra Biosciences in the second quarter valued at $139,161,000. BlackRock Inc. bought a new stake in shares of Tyra Biosciences in the 2nd quarter worth about $96,841,000. 5AM Venture Management LLC bought a new stake in shares of Tyra Biosciences in the 2nd quarter worth about $32,875,778. Janus Henderson Group PLC increased its position in shares of Tyra Biosciences by 32.5% during the 1st quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company's stock worth $148,867,000 after purchasing an additional 955,147 shares in the last quarter. Finally, Jennison Associates LLC acquired a new stake in shares of Tyra Biosciences during the 1st quarter worth about $24,222,000. 84.14% of the stock is currently owned by institutional investors. ## Tyra Biosciences Trading Down 6.7% The stock has a market capitalization of $1.42 billion, a P/E ratio of -10.00 and a beta of 0.73. The firm's fifty day moving average is $27.38 and its 200-day moving average is $31.41. Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Equities research analysts expect that Tyra Biosciences, Inc. will post -2.73 EPS for the current year. ## Tyra Biosciences Company Profile (Get Free Report) Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments. Tyra's lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder. ## Further Reading - Five stocks we like better than Tyra Biosciences - These 4 Companies Are Monetizing AI Today - Quantum and Rare Earths? Implications of the Pasqal/USAR Partnership - Lockheed's Stock Hasn't Priced In Its Own Backlog—Boeing's Might Already Have - Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Tyra Biosciences Right Now? Before you consider Tyra Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list. While Tyra Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ### Related Stocks - [TYRA.US](https://longbridge.com/en/quote/TYRA.US.md) - [BLK.US](https://longbridge.com/en/quote/BLK.US.md) - [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md) - [JHG.US](https://longbridge.com/en/quote/JHG.US.md) - [BTX.US](https://longbridge.com/en/quote/BTX.US.md) - [BIT.RT*.US](https://longbridge.com/en/quote/BIT.RT*.US.md) - [BDJ.US](https://longbridge.com/en/quote/BDJ.US.md) - [BSTZ.US](https://longbridge.com/en/quote/BSTZ.US.md) - [BIT.RT.US](https://longbridge.com/en/quote/BIT.RT.US.md) ## Related News & Research - [Farther Finance Advisors LLC Grows Stock Position in BlackRock $BLK](https://longbridge.com/en/news/301330492.md) - [‘We’re looking at a bubble here’: Experts including Ray Dalio and BlackRock CIO advise on how to protect your wealth as bond yields spike](https://longbridge.com/en/news/301504987.md) - [BlackRock heads into Q3 earnings with strong inflows and growth expectations](https://longbridge.com/en/news/301719921.md) - [TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY | TYRA Stock News](https://longbridge.com/en/news/287215316.md) - [OpenAI Reportedly in Talks With UAE Funds and BlackRock on USD30 billion Financing](https://longbridge.com/en/news/300978271.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**